PMID- 35600348
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220716
IS  - 2234-943X (Print)
IS  - 2234-943X (Electronic)
IS  - 2234-943X (Linking)
VI  - 12
DP  - 2022
TI  - Impact of Type 2 Diabetes Mellitus on Endometrial Cancer Survival: A Prospective 
      Database Analysis.
PG  - 899262
LID - 10.3389/fonc.2022.899262 [doi]
LID - 899262
AB  - PURPOSE: Type 2 diabetes mellitus (T2DM) is an established risk factor for 
      endometrial cancer but its impact on endometrial cancer survival outcomes is 
      unclear. The aim of this study was to investigate whether pre-existing T2DM 
      impacts survival outcomes in endometrial cancer. PATIENTS AND METHODS: Women 
      diagnosed with endometrial cancer were recruited to a single centre prospective 
      cohort study. Relevant sociodemographic and clinico-pathological data were 
      recorded at baseline. T2DM status was based on clinical and biochemical 
      assessment, verified by general practitioner records and analysed in relation to 
      overall, cancer-specific and recurrence-free survival using Kaplan-Meier 
      estimation and multivariable Cox-regression. RESULTS: In total, 533 women with 
      median age and BMI of 66 years (Interquartile range (IQR), 56, 73) and 32kg/m(2) 
      (IQR 26, 39) respectively, were included in the analysis. The majority had 
      low-grade (67.3%), early-stage (85.1% stage I/II), endometrial cancer of 
      endometrioid histological phenotype (74.7%). A total of 107 (20.1%) had 
      pre-existing T2DM. Women with T2DM had a two-fold increase in overall mortality 
      (adjusted HR 2.07, 95%CI 1.21-3.55, p=0.008), cancer-specific mortality (adjusted 
      HR 2.15, 95% CI 1.05-4.39, p=0.035) and recurrence rates (adjusted HR 2.22, 95% 
      CI 1.08-4.56, p=0.030), compared to those without, in multivariable analyses. 
      CONCLUSION: T2DM confers an increased risk of death in endometrial cancer 
      patients. Well-designed longitudinal studies with large sample sizes are now 
      needed to confirm these findings.
CI  - Copyright (c) 2022 Njoku, Agnew and Crosbie.
FAU - Njoku, Kelechi
AU  - Njoku K
AD  - Division of Cancer Sciences, School of Medical Sciences, Faculty of Biology, 
      Medicine and Health, St Mary's Hospital, University of Manchester, Manchester, 
      United Kingdom.
AD  - Stoller Biomarker Discovery Centre, Institute of Cancer Sciences, Faculty of 
      Biology, Medicine and Health, University of Manchester, Manchester, United 
      Kingdom.
FAU - Agnew, Heather J
AU  - Agnew HJ
AD  - Division of Cancer Sciences, School of Medical Sciences, Faculty of Biology, 
      Medicine and Health, St Mary's Hospital, University of Manchester, Manchester, 
      United Kingdom.
FAU - Crosbie, Emma J
AU  - Crosbie EJ
AD  - Division of Cancer Sciences, School of Medical Sciences, Faculty of Biology, 
      Medicine and Health, St Mary's Hospital, University of Manchester, Manchester, 
      United Kingdom.
AD  - Department of Obstetrics and Gynaecology, Manchester University NHS Foundation 
      Trust, Manchester Academic Health Science Centre, Manchester, United Kingdom.
LA  - eng
PT  - Journal Article
DEP - 20220505
PL  - Switzerland
TA  - Front Oncol
JT  - Frontiers in oncology
JID - 101568867
PMC - PMC9117616
OTO - NOTNLM
OT  - endometrial cancer
OT  - mortality
OT  - prognosis
OT  - survival
OT  - type 2 diabetes mellitus
COIS- The authors declare that the research was conducted in the absence of any 
      commercial or financial relationships that could be construed as a potential 
      conflict of interest.
EDAT- 2022/05/24 06:00
MHDA- 2022/05/24 06:01
PMCR- 2022/01/01
CRDT- 2022/05/23 03:53
PHST- 2022/03/18 00:00 [received]
PHST- 2022/04/14 00:00 [accepted]
PHST- 2022/05/23 03:53 [entrez]
PHST- 2022/05/24 06:00 [pubmed]
PHST- 2022/05/24 06:01 [medline]
PHST- 2022/01/01 00:00 [pmc-release]
AID - 10.3389/fonc.2022.899262 [doi]
PST - epublish
SO  - Front Oncol. 2022 May 5;12:899262. doi: 10.3389/fonc.2022.899262. eCollection 
      2022.